Researchers at the Mayo Clinic Cancer Center are studying a new potential treatment for chimeric antigen receptor (CAR-T cell therapy) T-cell therapy for multiple myeloma. His findings were published on Friday, June 24 a The Lancet.
“CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person’s immune system by engineering their T cells recognize and destroy cancer cells“says Yi Lin, MD, a Mayo Clinic hematologist and lead author of the study.
Dr. Lin said the Food and Drug Administration approved in March the idecabtagene vicleucel, the first CAR-T cell treatment for multiple myeloma. “Today we are working to achieve another potential CAR-T cell treatment for multiple myeloma,” says Dr. Lin.
Dr. Lin says the CARTITUDE-1 study is a 1B / II registration phase clinical trial. The assay tested the B-cell maturation antigen for CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), in patients with multiple myeloma who received at least three previous lines of therapy. with standard drugs, including proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies
“Cilta-cel is made up of the patient’s own T cells that have been genetically engineered and administered as a single dose infusion,” says Dr. Lin.
Dr. Lin says the overall response rate to treatment was 97%, while the complete response rate and progression-free survival were 67% and 77%, respectively. The overall survival rate was 89%.
“Updates from this study were also recently presented to the American Society of Clinical Oncology annual meeting, which occurred after our work was accepted for publication in The Lancet“Our ASCO presentation showed a continued in-depth response for patients receiving this therapy, with a complete response rate of 80%,” says Dr. Lin. “These are very impressive results for myeloma patients who have already gone through many lines of therapy for their disease.”
In the future, Dr. Lin says it will be important to better understand the clinical features of patients who have experienced lasting remissions of this therapy and the mechanisms behind relapsing patients.
“Although no formal comparisons can be made between two separate single-arm studies on ide-cel and cilta-cel, the impressive high response rate and progression-free survival of patients treated with cilta-cel are very exciting, ”says Dr. Lin.
He warns, however, that the possible translation of this research into individualized clinical therapy will require resolving many logistical details, including ensuring that the transition from manufacturing to research to a commercial product remains reliable.
Citation: Researchers study new CAR-T cell therapy for multiple myeloma (2021, June 26) recovered on June 26, 2021 at https://medicalxpress.com/news/2021-06-potential-car -t-cell-therapy-multiple. html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.